Cargando…

microRNA-202激活JNK/SAPK信号通路增强多发性骨髓瘤细胞药物敏感性的研究

OBJECTIVE: To explore the role of miR-202 in multiple myeloma (MM) cells, and study the regulation of miR-202 on drug sensitivity of MM cells. METHODS: miR-202 and BAFF mRNA levels were detected by real-time PCR. U266 cells were transfected with miR-202-mimics, miR-202-inhibitor, siBAFF and their ne...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348509/
https://www.ncbi.nlm.nih.gov/pubmed/27995886
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.11.012
_version_ 1783556842118447104
collection PubMed
description OBJECTIVE: To explore the role of miR-202 in multiple myeloma (MM) cells, and study the regulation of miR-202 on drug sensitivity of MM cells. METHODS: miR-202 and BAFF mRNA levels were detected by real-time PCR. U266 cells were transfected with miR-202-mimics, miR-202-inhibitor, siBAFF and their negative controls. After above treatments, protein levels of Bcl-2 family and MAPK signaling pathway were detected by Western blot analysis, and the proliferation and apoptosis ability of MM cells were examined by WST-1, Annexin V-FLUOS assay, respectively. RESULTS: The results showed that the expression of miR-202 in CD138+ MM cells (0.304±0.354) and U266 cells (0.052± 0.009) were lower than in normal controls (3.550 ± 1.126) (P<0.001, P=0.009), whereas BAFF mRNA levels (5.700 ± 0.734, 9.576 ± 2.887) were higher than in normal controls (1.819 ± 0.853) (P<0.001, P= 0.006). The proliferation ability of U266 cells transfected with miR-202 mimics was significantly inhibited than in control group [(56.04±0.021)% vs (18.89±0.32)%, P=0.002]. The result of Western blot showed that the expression of Bcl-2 decreased by about 24%, and the expression of Bax increased by about 124% in cells transfected with miR-202 mimics. The apoptosis rate in cells transfected with miR-202 mimics was significantly more than in control group [(49.60±4.89)% vs (26.20±1.28)%, P=0.029]. The apoptosis rate in miR-202 mimics combined with Bort group (51.23±5.41)% was higher as compared with Bort treatment alone (31.70±4.40)% or miR-202 mimics control combined with Bort group (27.94±4.04)%, (P=0.047, P= 0.028), whereas the apoptosis rate in miR-202 mimics combined with Thal or Dex had no significant difference compared with miR-202 mimics control [(11.66±1.91)% vs (10.63±1.74)%, P=0.700; (16.35± 1.32)% vs (17.43 ± 1.95)%, P=0.400]. The inhibitory rate of cell growth in miR-202 mimics combined with Bort group was higher as compared with Bort treatment alone [(36.93±5.98)% vs (18.18±4.10)%, P= 0.029]. The expressions of p-JNK protein decreased in U266 cells transfected with miR-202 mimics and treated with Bort. CONCLUSION: miR-202 mimics combined with Bort could inhibit proliferation and induce apoptosis of U266 cells through negative regulating target gene BAFF, which further inhibited the JNK/SAPK signaling pathway.
format Online
Article
Text
id pubmed-7348509
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73485092020-07-16 microRNA-202激活JNK/SAPK信号通路增强多发性骨髓瘤细胞药物敏感性的研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the role of miR-202 in multiple myeloma (MM) cells, and study the regulation of miR-202 on drug sensitivity of MM cells. METHODS: miR-202 and BAFF mRNA levels were detected by real-time PCR. U266 cells were transfected with miR-202-mimics, miR-202-inhibitor, siBAFF and their negative controls. After above treatments, protein levels of Bcl-2 family and MAPK signaling pathway were detected by Western blot analysis, and the proliferation and apoptosis ability of MM cells were examined by WST-1, Annexin V-FLUOS assay, respectively. RESULTS: The results showed that the expression of miR-202 in CD138+ MM cells (0.304±0.354) and U266 cells (0.052± 0.009) were lower than in normal controls (3.550 ± 1.126) (P<0.001, P=0.009), whereas BAFF mRNA levels (5.700 ± 0.734, 9.576 ± 2.887) were higher than in normal controls (1.819 ± 0.853) (P<0.001, P= 0.006). The proliferation ability of U266 cells transfected with miR-202 mimics was significantly inhibited than in control group [(56.04±0.021)% vs (18.89±0.32)%, P=0.002]. The result of Western blot showed that the expression of Bcl-2 decreased by about 24%, and the expression of Bax increased by about 124% in cells transfected with miR-202 mimics. The apoptosis rate in cells transfected with miR-202 mimics was significantly more than in control group [(49.60±4.89)% vs (26.20±1.28)%, P=0.029]. The apoptosis rate in miR-202 mimics combined with Bort group (51.23±5.41)% was higher as compared with Bort treatment alone (31.70±4.40)% or miR-202 mimics control combined with Bort group (27.94±4.04)%, (P=0.047, P= 0.028), whereas the apoptosis rate in miR-202 mimics combined with Thal or Dex had no significant difference compared with miR-202 mimics control [(11.66±1.91)% vs (10.63±1.74)%, P=0.700; (16.35± 1.32)% vs (17.43 ± 1.95)%, P=0.400]. The inhibitory rate of cell growth in miR-202 mimics combined with Bort group was higher as compared with Bort treatment alone [(36.93±5.98)% vs (18.18±4.10)%, P= 0.029]. The expressions of p-JNK protein decreased in U266 cells transfected with miR-202 mimics and treated with Bort. CONCLUSION: miR-202 mimics combined with Bort could inhibit proliferation and induce apoptosis of U266 cells through negative regulating target gene BAFF, which further inhibited the JNK/SAPK signaling pathway. Editorial office of Chinese Journal of Hematology 2016-11 /pmc/articles/PMC7348509/ /pubmed/27995886 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.11.012 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
microRNA-202激活JNK/SAPK信号通路增强多发性骨髓瘤细胞药物敏感性的研究
title microRNA-202激活JNK/SAPK信号通路增强多发性骨髓瘤细胞药物敏感性的研究
title_full microRNA-202激活JNK/SAPK信号通路增强多发性骨髓瘤细胞药物敏感性的研究
title_fullStr microRNA-202激活JNK/SAPK信号通路增强多发性骨髓瘤细胞药物敏感性的研究
title_full_unstemmed microRNA-202激活JNK/SAPK信号通路增强多发性骨髓瘤细胞药物敏感性的研究
title_short microRNA-202激活JNK/SAPK信号通路增强多发性骨髓瘤细胞药物敏感性的研究
title_sort microrna-202激活jnk/sapk信号通路增强多发性骨髓瘤细胞药物敏感性的研究
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348509/
https://www.ncbi.nlm.nih.gov/pubmed/27995886
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.11.012
work_keys_str_mv AT microrna202jīhuójnksapkxìnhàotōnglùzēngqiángduōfāxìnggǔsuǐliúxìbāoyàowùmǐngǎnxìngdeyánjiū
AT microrna202jīhuójnksapkxìnhàotōnglùzēngqiángduōfāxìnggǔsuǐliúxìbāoyàowùmǐngǎnxìngdeyánjiū
AT microrna202jīhuójnksapkxìnhàotōnglùzēngqiángduōfāxìnggǔsuǐliúxìbāoyàowùmǐngǎnxìngdeyánjiū
AT microrna202jīhuójnksapkxìnhàotōnglùzēngqiángduōfāxìnggǔsuǐliúxìbāoyàowùmǐngǎnxìngdeyánjiū
AT microrna202jīhuójnksapkxìnhàotōnglùzēngqiángduōfāxìnggǔsuǐliúxìbāoyàowùmǐngǎnxìngdeyánjiū
AT microrna202jīhuójnksapkxìnhàotōnglùzēngqiángduōfāxìnggǔsuǐliúxìbāoyàowùmǐngǎnxìngdeyánjiū
AT microrna202jīhuójnksapkxìnhàotōnglùzēngqiángduōfāxìnggǔsuǐliúxìbāoyàowùmǐngǎnxìngdeyánjiū